Answers are grounded in this paper and cite their sources.
Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder often accompanied by renal injury. Current therapies face challenges due to adverse effects, necessitating safer alternatives. Cornuside, a bioactive compound from Cornus officinalis, demonstrates anti-inflammatory properties, but its role in SLE remains unexplored. This study investigated cornuside’s protective effects in pristane-induced SLE mice. Results showed cornuside significantly reduced proteinuria, paw swelling, and renal inflammation. Mechanistically, cornuside suppressed proinflammatory cytokines (IL-1β, IL-6, IL-17, TNF-α), and activated Nrf-2/ARE-mediated antioxidant responses (HO-1 upregulation). These findings highlight cornuside’s potential as a novel therapeutic agent for SLE-associated renal injury.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: